^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IO-312
i
Other names: IO-312
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Immune-Onc Therap
Drug class:
CD3 agonist, ILT-3 inhibitor
Related drugs:
12ms
Novel Myeloid Checkpoint Inhibitors Targeting the LILRB (ILT) Family Members (PEGS 2023)
These include IO-108, an antagonist antibody targeting LILRB2 (ILT4), in Phase I clinical development for solid tumors and IO-202; an antagonist antibody targeting LILRB4 (ILT3), in Phase I clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class antagonist antibody targeting LAIR1; IO-312, a novel bispecific antibody targeting LILRB4 and CD3 (LILRB4 x CD3); and multiple undisclosed programs.
Checkpoint inhibition
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
|
IO-202 • IO-106 • IO-108 • IO-312
Share via
